RIGEL PHARMACEUTICALS INC (RIGL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 150M 300M 450M FY16: 20.4M FY17: 4.5M FY18: 44.5M FY19: 59.3M FY20: 108.6M FY21: 149.2M FY22: 120.2M FY23: 116.9M FY24: 179.3M FY25: 294.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 100M 200M 300M FY18: 44.2M FY19: 58.4M FY20: 107.7M FY21: 148.2M FY22: 118.5M FY23: 109.8M FY24: 160.6M FY25: 274.7M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY09: -112M FY10: 35.3M FY11: -86.4M FY12: -99.4M FY13: -89.5M FY14: -91.2M FY15: -51.7M FY16: -69.7M FY17: -79.6M FY18: -72.7M FY19: -69.1M FY20: -29M FY21: -12.5M FY22: -55.5M FY23: -20.5M FY24: 24.2M FY25: 125.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-150M 0 150M 300M 450M FY09: -111.5M FY10: 37.9M FY11: -86M FY12: -98.8M FY13: -89M FY14: -90.9M FY15: -51.5M FY16: -69.2M FY17: -78M FY18: -70.5M FY19: -66.9M FY20: -29.7M FY21: -17.9M FY22: -58.6M FY23: -25.1M FY24: 17.5M FY25: 367M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 7M 14M 21M FY18: 287K FY19: 906K FY20: 895K FY21: 1.1M FY22: 1.7M FY23: 7.1M FY24: 18.6M FY25: 19.6M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-105M -70M -35M 0 35M 70M 105M FY09: -102.8M FY10: 46.7M FY11: -69.4M FY12: -85.2M FY13: -86.1M FY14: -69.8M FY15: -23.4M FY16: -75.9M FY17: -77.6M FY18: -58.8M FY19: -41.5M FY20: -52.2M FY21: 5.9M FY22: -73.8M FY23: -5.7M FY24: 31.5M FY25: 75.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-105M -70M -35M 0 35M 70M 105M FY09: -102.9M FY10: 43.2M FY11: -71.7M FY12: -88.6M FY13: -87.3M FY14: -70.2M FY15: -24M FY16: -76.7M FY17: -77.7M FY18: -59.9M FY19: -43M FY20: -53.4M FY21: 5.3M FY22: -74.2M FY10 FY12 FY14 FY16 FY18 FY20 FY22

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 60M 120M 180M FY09: 40.9M FY10: 52.6M FY11: 63.3M FY12: 75M FY13: 87.3M FY14: 87.7M FY19: 167.4M FY20: 168.8M FY21: 170.5M FY22: 17M FY23: 17.4M FY24: 17.7M FY25: 18.8M FY09 FY11 FY13 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.00 0.00 7.00 14.00 21.00 Q4 '11: -1.39 Q1 '12: -1.31 Q2 '12: -1.29 Q3 '12: -1.40 Q4 '12: -1.32 Q1 '13: -1.29 Q2 '13: -1.20 Q3 '13: -1.11 Q4 '13: -1.01 Q1 '14: -0.97 Q2 '14: -1.00 Q3 '14: -0.97 Q4 '14: -1.03 Q1 '15: -0.99 Q2 '15: -0.86 Q3 '15: -0.70 Q4 '15: -0.59 Q1 '16: -0.57 Q2 '16: -0.56 Q3 '16: -0.72 Q4 '16: -0.74 Q1 '17: -0.68 Q2 '17: -0.69 Q3 '17: -0.59 Q4 '17: -0.61 Q1 '18: -0.65 Q2 '18: -0.65 Q3 '18: -0.65 Q4 '18: -0.45 Q1 '19: -0.39 Q2 '19: -0.35 Q3 '19: -0.28 Q4 '19: -0.40 Q1 '20: -0.16 Q2 '20: -0.14 Q3 '20: -0.15 Q4 '20: -0.17 Q1 '21: -0.08 Q2 '21: -0.06 Q3 '21: -0.10 Q4 '21: -0.11 Q1 '22: -0.49 Q2 '22: -0.49 Q3 '22: -0.48 Q4 '22: -3.44 Q1 '23: -3.36 Q2 '23: -3.66 Q3 '23: -3.88 Q4 '23: -0.74 Q1 '24: -1.13 Q2 '24: -0.81 Q3 '24: 0.22 Q4 '24: 0.98 Q1 '25: 2.08 Q2 '25: 5.42 Q3 '25: 6.18 Q4 '25: 19.47 Q1 '26: 19.28 Q2 '26: 16.88 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.